Abstract
Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have